

Ferritin - Instructions for use

R1: 1x14.5 mL • REF A R3330000052

R2: 1x5 mL





SUMMARY AND EXPLANATION OF THE TEST

The plasma Ferritin concentration declines very early in the development of iron deficiency.

On the other hand, a large number of chronic diseases result in increased serum Ferritin concentrations. These diseases include chronic infections, chronic inflammatory disorders such as rheumatoid arthritis or renal disease, Gaucher's disease, and numerous types of malignancies, especially lymphomas, leukaemias, breast cancer and neuroblastoma. Increase in plasma Ferritin concentration also occurs in viral hepatitis or following toxic liver injury because of release of Ferritin from damaged liver cells. Plasma Ferritin concentration is also increased with increases of iron stores, as seen in patients with hemosiderosis or hemochromatosis. Besides the use of Ferritin as an iron metabolism parameter, Ferritin as also gained importance as a tumour marker for therapeutic drug monitoring and follow-up.

PRINCIPLE OF THE TEST

Measurement of antigen-antibody reaction by the end-point method.

Ferritin Reagent Kit Code R3330000042

Reagent 1 (R1) - Buffer - 1 x 14,5 mL/vial Reagent 2 (R2) - Latex - 1 x 5 mL/vial

Each vial is ready to use and contains

Reagent 1:	Conc.	U.M.
Hepes Buffer	/	/
Sodium azide	0,95	g/L
Reagent 2:	Conc.	U.M.
Solution of suspended latex microparticles sensitized with rabbit IgG anti- uman ferritin .	1	1

Reagent Preparation:

Liquids reagents ready for use.

Storage and Stability:

If stored at 2 - 8°C avoiding direct light, the reactants remain stable until the expiration date printed on the label.

Stability in the instrument is at least 4 weeks if contamination is avoided. Do not freeze. Do not freeze the reagents

EQUIPMENT / ACCESSORIES REQUIRED AND NOT SUPPLIED

General laboratory equipment

Saline (9 g/L)

Calibrators and/or Control

(Pooled human serum, liquid and stabilized. Contains 0.95 g/L sodium azide. Value is stated in the

PRECAUTIONS AND LIMITATIONS

For in vitro diagnostic use.

Only experienced laboratory personnel should use this test and handling should be in agreement with Good Laboratory Practice (GLP).

Reagents from different lots must not be interchanged.

Safety Precautions

- Each donor unit used in the preparation of the reagents, standards and controls was found to be negative for the presence of HIV1 and HIV2 antibodies, as well as for the hepatitis B surface antigen and anti-hepatitis C antibodies, using a method approved by the FDA
- Do not pipet by mouth.
- Do not smoke, eat or apply cosmetics in areas in which patients' samples or kit reagents are
- Cuts, abrasions, and other skin lesions should be properly protected with an appropriate waterproof dressing.
- Take care to avoid self-inoculation, splashing of mucous membranes or generation of aerosols.
- Laboratory gloves should be worn while handling patients' samples or disposing of solid or
- In addition to the eventual risk indications regarding the active components, the reagents contain inactive components such as preservatives (e.g. sodium azide or others) and detergents. The total concentrations of these components is lower than the limits reported by the current directive sand following modification and amendments. However, it is recommended to handle reagents carefully, to avoid ingestion and contact with eyes, skin and mucus membranes and to use laboratory reagents according to good laboratory
- All human samples must be handled and disposed of as potentially infectious materials
- For information about safe handling, read carefully the Material Safety Data Sheet (MSDS).

Disposal of Reagents

Disposal of reagents must be performed in accordance with the EC regulations regarding waste, or the local national or regional legislation.

SPECIMEN COLLECTION AND STORAGE

If the test can not be carried out on the same day, the serum may be stored at 2 - 8°C for 48 hours. If stored for a longer period, the sample should be frozen.

ASSAY PROCEDURE

Allow reagents to reach working temperature before using

Quality control

It's necessary, each time the kit is used, to perform the quality controls and to check that values obtained are within the acceptance range provided in the insert. Each laboratory should establish its own mean and standard deviation and adopt a quality control program to monitor laboratory testing.

All applications not explicitly approved by I.S.E. S.r.I. cannot be guaranteed in terms of performance, and must therefore be established by the operator.

Procedures

Sample/Control/Standard: Ready for use. Reference curve: Ferritin standard kit R-1300002901. Use saline 9 g/L as zero point.

EXPECTED VALUES

15 - 200 ng/mL Woman:

Reference values are considered indicative since each laboratory should establish reference ranges for its own patient population. The analytical results should be evaluated with other information coming from patient's clinical history.

PERFORMANCE CHARACTERISTICS

The performance characteristics for the Ferritin reagents were measured on a clinical chemistry analyzer according to the procedure R1: 150 µL and R2: 50µL

Measuring Range: 0 - 500 ng/mL 5.0 ng/mL Detection Limit: No Risk Hookeffect:

Precision:		Low	Medium	High
[%CV]	Intra-Run	0.76	0.63	0.61
	Inter-Run	4.14	3.8	4.11
Accuracy:	Control	Assigned	Measured	
[mg/dL]	Aptec	85.2 (72.4-98.0)	92.1	
	Aptec	224 (190-258)	221.1	
	Siemens	87.7 (70.2-105.2)	82.5]

Specificity: Monospecific No interference for: Interferences:

Heparin (50 mg/dL), Na Cl (1000 mg/dL), Triglyceride (2500 mg/dL), Bilirubin (30 mg/dL), Heamoglobin (250 mg/dL), EDTA (5 mg/mL)

 $\underline{\text{Comparison with Turbidimetry method}}$: y = 0.9261x +015.5596 / r = 0.9868 Stability at 2°-8°C: at least 16 months after production

BIBLIOGRAPHY

Limitations:

- Lipzchitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med. 1974; 290(22): 1213-1216
- Worwood M. Ferritin in human tissues and serum. Clin Heamatol. 1982; 11(2): 275-307
- Worwood M. Serum ferritin. Clin Sci(Lond)1986; 70(3): 215-220
- Warr GW, Magor KE, Higgins DA. IgY: clues to the origins of modern antibodies. Immunology Today 1998; 16:92-8.



Numero lotto / Lot numer

IVD

Consultare la metodica operativa / consult instructions for use



Per uso diagnostico in-vitro / For in-vitro diagnostic use



Prodotto da / manufactured by



Data di scadenza / expiry date

Temp. Di Conservazione / storage temperature

